Article
Biochemistry & Molecular Biology
Jin Kono, Masakatsu Ueda, Atsushi Sengiku, Sylvia O. Suadicani, Osamu Ogawa, Hiromitsu Negoro
Summary: The study suggests that urothelial Cx43 mediated ATP signaling and coordination of urothelial activity are essential for proper perception and regulation of responses to bladder distension in the animals' awake, active phase. This research highlights the significant role of Cx43 in bladder function.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Jia-Fong Jhang, Han-Chen Ho, Yuan-Hsiang Hsu, Yuan-Hong Jiang, Hann-Chorng Kuo
Summary: This study found that patients with recurrent urinary tract infection (rUTI) have bladder defects and elevated urine inflammatory markers. After treatment with platelet-rich plasma (PRP) injections, some patients showed improvement in bladder defects.
Review
Pharmacology & Pharmacy
Shupeng Wang, Shaohua Jin, Qinghai Shu, Song Wu
Summary: Bladder cancer poses a high risk of recurrence, with intravesical drug instillation being the primary treatment. However, the therapeutic effect is limited by bladder penetrating barriers, leading to low drug concentration and increased recurrence and progression rates of bladder cancer. Various strategies have been developed to overcome these barriers and improve intravesical treatment efficacy.
Article
Food Science & Technology
Hodan Ibrahim, Jacquie Maignel, Fraser Hornby, Donna Daly, Matthew Beard
Summary: This review discusses the current evidence of BoNT/A's effect on bladder sensation, potential mechanisms by which it exerts these effects, and recent advances in understanding its action in bladder tissue.
Article
Physiology
B. Malique Jones, Gerald C. Mingin, Nathan R. Tykocki
Summary: Mast cells and degranulation of inflammatory mediators contribute to lower urinary tract symptoms. This study found that the mast cell stimulator compound 48/80 alters urinary bladder smooth muscle contractility via urothelium-dependent inflammatory pathways, independent of mast cells. These findings suggest that compound 48/80 could be used to manage inflammatory nonneurogenic bladder hyperactivity.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
(2023)
Article
Oncology
Jae Hoon Chung, Wan Song, Minyong Kang, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Hyun Hwan Sung
Summary: A study analyzing data from 1,095 UTUC patients who underwent RNUx found that factors like history of bladder cancer, multifocal tumors, and preoperative ureteroscopy use were associated with intravesical recurrence. Active assessment for intravesical recurrence is recommended for at least 36 months post-RNUx.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Nicole M. Gilbert, Valerie P. O'Brien, Chevaughn Waller, Ekatherina Batourina, Cathy Lee Mendelsohn, Amanda L. Lewis
Summary: Gardnerella, a common member of the female urinary microbiome, is associated with urological disorders in women. In a mouse model, Gardnerella inoculation leads to urothelial exfoliation and activation of pathways involved in inflammation and immunity. Bladder exposure to Gardnerella also increases susceptibility to subsequent urinary tract infection.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Review
Pharmacology & Pharmacy
Pooja Jain, Himanshu Kathuria, Munira Momin
Summary: Bladder cancer is the 10th most common malignancy worldwide with a 5-year survival rate of 75%, but 70% of the cases develop chemoresistance and progress to the muscle invasive stage. Nanotechnology has shown promise in targeted drug delivery to bladder cancer cells, offering potential for better treatment management.
PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Biochemistry & Molecular Biology
Natalia Zeber-Lubecka, Maria Kulecka, Katarzyna Zaleska-Oracka, Michalina Dabrowska, Aneta Balabas, Ewa E. Hennig, Magdalena Szymanek-Szwed, Michal Mikula, Beata Jurkiewicz, Jerzy Ostrowski
Summary: The aim of this study is to determine the molecular differences between the bladder body and trigonal urothelia. The analysis of transcriptomes and microbiomes revealed functional differences between the two regions and significant differences in bacterial taxa in urine.
Article
Biochemistry & Molecular Biology
Emma Mitidieri, Annalisa Pecoraro, Erika Esposito, Vincenzo Brancaleone, Carlotta Turnaturi, Luigi Napolitano, Vincenzo Mirone, Ferdinando Fusco, Giuseppe Cirino, Raffaella Sorrentino, Giulia Russo, Annapina Russo, Roberta dEmmanuele di Villa Bianca
Summary: The urothelium plays an important role in bladder homeostasis through the hydrogen sulfide pathway and beta(3) adrenoceptor-mediated relaxation. The study demonstrates the relevance of urothelial beta(3) adrenoceptors in regulating bladder tone and supports the use of beta(3) agonists in patients with an overactive bladder.
Article
Pharmacology & Pharmacy
Zhinoos Taidi, Tommy Zhou, Kate H. Moore, Kylie J. Mansfield, Lu Liu
Summary: Inflammatory conditions of the urinary bladder are associated with urothelial damage and loss of function. The purinergic P2X7 receptor plays a role in such inflammatory conditions and may be a new therapeutic target for bladder inflammation.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Oncology
John P. Sfakianos, Zeynep Gul, Shahrokh F. Shariat, Surena F. Matin, Siamak Daneshmand, Elizabeth Plimack, Seth Lerner, Morgan Roupret, Sumanta Pal
Summary: Urothelial carcinoma of the bladder and upper tract urothelial carcinoma share mutations in similar genes but at different frequencies, which likely contribute to their distinct behaviors and metachronous recurrences. Tailored treatment options specific to tumors of different locations based on their genomic features are recommended.
EUROPEAN UROLOGY ONCOLOGY
(2021)
Review
Biology
Nassib Abou Heidar, Tariq A. Bhat, Usma Shabir, Ahmed A. Hussein
Summary: Bladder cancer is a common cancer worldwide, and most patients have non-muscle invasive disease. Transurethral resection of bladder tumor (TURBT) with adjuvant intravesical therapy is the standard treatment. Urine, previously thought to be sterile, has been found to have a urinary microbiome associated with urological diseases. The urinary microbiome may serve as a biomarker for risk stratification and response prediction in bladder cancer.
Article
Urology & Nephrology
Fabiana Cancrini, Floriane Michel, Olivier Cussenot, Hussa Alshehhi, Eva Comperat, Veronique Phe
Summary: The aim of this study was to evaluate the expression of different immunohistochemical markers in bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis infection. Tissue samples from patients with neurogenic bladder and bladder carcinoma, patients with urinary schistosomiasis infection and bladder carcinoma, and patients with urinary schistosomiasis without bladder carcinoma were compared. The expression of markers was analyzed using immunohistochemistry. The results showed that there was no difference in the expression of markers between the neurogenic bladder and urinary schistosomiasis groups, but certain markers were significantly higher in the TCC and SCC subgroups compared to the control group without bladder carcinoma.
WORLD JOURNAL OF UROLOGY
(2022)
Article
Oncology
Thomas van Doeveren, Jose A. Nakauma-Gonzalez, Andrew S. Mason, Geert J. L. H. van Leenders, Tahlita C. M. Zuiverloon, Ellen C. Zwarthoff, Isabelle C. Meijssen, Angelique C. van der Made, Antoine G. van Der Heijden, Kees Hendricksen, Bas W. G. van Rhijn, Charlotte S. Voskuilen, Job van Riet, Winand N. M. Dinjens, Hendrikus J. Dubbink, Harmen J. G. van de Werken, Joost L. Boormans
Summary: By sequencing genes in 15 UTUC patients treated by RNU, it was found that the majority of patients had a clonal relationship between UTUC and subsequent UCB, supporting the idea that UCBs following UTUC surgery are primarily clonally derived recurrences.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Martin Fenner, Christoph Oing, Annette Dieing, Thomas Gauler, Karin Oechsle, Anja Lorch, Marcus Hentrich, Hans-Georg Kopp, Carsten Bokemeyer, Friedemann Honecker
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2019)
Editorial Material
Oncology
Richard J. Rebello, Christoph Oing, Silke Gillessen, Robert G. Bristow
CLINICAL CANCER RESEARCH
(2019)
Review
Pharmacology & Pharmacy
Winfried Alsdorf, Christoph Seidel, Carsten Bokemeyer, Christoph Oing
EXPERT OPINION ON PHARMACOTHERAPY
(2019)
Review
Andrology
C. Oing, M. A. Skowron, C. Bokemeyer, D. Nettersheim
Article
Andrology
A. Radtke, K. -P. Dieckmann, F. Grobelny, A. Salzbrunn, C. Oing, W. Schulze, G. Belge
Article
Oncology
Christoph Oing, Marcus Hentrich, Anja Lorch, Dietrich Glaeser, Holger Rumpold, Sebastian Ochsenreither, Stephan Richter, Annette Dieing, Stefanie Zschaebitz, Ronnie Rodrigues Pereira, Carsten Bokemeyer, Christoph Seidel
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2020)
Article
Oncology
Joao Lobo, Catarina Guimaraes-Teixeira, Daniela Barros-Silva, Vera Miranda-Goncalves, Vania Camilo, Rita Guimaraes, Mariana Cantante, Isaac Braga, Joaquina Mauricio, Christoph Oing, Friedemann Honecker, Daniel Nettersheim, Leendert H. J. Looijenga, Rui Henrique, Carmen Jeronimo
Article
Oncology
Mohamed E. Elsesy, Su Jung Oh-Hohenhorst, Anastassia Loeser, Christoph Oing, Sally Mutiara, Sabrina Koecher, Stefanie Meien, Alexandra Zielinski, Susanne Burdak-Rothkamm, Derya Tilki, Hartwig Huland, Rudolf Schwarz, Cordula Petersen, Carsten Bokemeyer, Kai Rothkamm, Wael Y. Mansour
Review
Urology & Nephrology
Michal Chovanec, Jakob Lauritsen, Mikkel Bandak, Christoph Oing, Gry Gundgaard Kier, Michael Kreiberg, Josephine Rosenvilde, Thomas Wagner, Carsten Bokemeyer, Gedske Daugaard
Summary: The majority of testicular germ cell tumour (TGCT) patients are cured, but face potential late adverse effects and reduced quality of life. Certain treatments may increase the risk of cardiovascular disease for survivors in the long term.
NATURE REVIEWS UROLOGY
(2021)
Article
Medicine, General & Internal
Richard J. Rebello, Christoph Oing, Karen E. Knudsen, Stacy Loeb, David C. Johnson, Robert E. Reiter, Silke Gillessen, Theodorus Van der Kwast, Robert G. Bristow
Summary: Prostate cancer is a prevalent disease among men, with key genetic alterations including gene fusions, oncogene amplification, and mutations in androgen receptors. Treatment options range from active surveillance to surgery and radiotherapy for localized disease.
NATURE REVIEWS DISEASE PRIMERS
(2021)
Article
Oncology
Vera Miranda-Goncalves, Joao Lobo, Catarina Guimaraes-Teixeira, Daniela Barros-Silva, Rita Guimaraes, Mariana Cantante, Isaac Braga, Joaquina Mauricio, Christoph Oing, Friedemann Honecker, Daniel Nettersheim, Leendert H. J. Looijenga, Rui Henrique, Carmen Jeronimo
Summary: The study found significant differences in the expression of various m(6)A modifiers in cell lines representing different classes of GCTs, as well as changes after treatment with all-trans retinoic acid. Knockdown of VIRMA resulted in disruption of the methyltransferase complex, decreased m(6)A abundance, reduced tumor aggressiveness, and increased sensitivity to cisplatin treatment both in vitro and in vivo. Enhanced response to cisplatin after VIRMA knockdown was associated with increased DNA damage and downregulation of specific genes related to DNA repair.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Dennis M. Timmerman, Thomas F. Eleveld, Sruthi Sriram, Lambert C. J. Dorssers, Ad J. M. Gillis, Silvia Schmidtova, Katarina Kalavska, Harmen J. G. van de Werken, Christoph Oing, Friedemann Honecker, Michal Mego, Leendert H. J. Looijenga
Summary: In male type II germ cell tumors (GCTs), cisplatin resistance and poor clinical outcome are strongly associated with the status of 3p25.3. Genomic profiling based on this gene can help improve risk stratification in male patients with type II GCT.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Mohamed E. Elsesy, Su Jung Oh-Hohenhorst, Christoph Oing, Alicia Eckhardt, Susanne Burdak-Rothkamm, Malik Alawi, Christian Mueller, Ulrich Schueller, Tobias Maurer, Gunhild von Amsberg, Cordula Petersen, Kai Rothkamm, Wael Y. Mansour
Summary: This study provides preclinical models for castration-resistant prostate cancer (CRPC) that can predict homologous recombination repair (HRR) defects and the sensitivity to olaparib and cisplatin. These models recapitulate the features of primary tumors, enabling individualized drug screening for tailored therapy recommendations.
MOLECULAR ONCOLOGY
(2023)
Editorial Material
Oncology
C. Oing, R. G. Bristow
Article
Oncology
Georg Richtig, Erika Richtig, Alexandra Boehm, Christoph Oing, Farastuk Bozorgmehr, Stephan Kruger, Barbara Kiesewetter, Christoph Zielinski, Anna S. Berghoff